05:48 PM EST, 12/18/2024 (MT Newswires) -- Quince Therapeutics ( QNCX ) filed a shelf registration statement with the US Securities and Exchange Commission Wednesday covering the potential sale of up to $200 million of securities from time to time in one or more offerings.

The statement covers common and preferred stock, debt securities, and warrants.

The company said it plans to use any net proceeds generated from the sale of the securities for working capital and general corporate purposes.

Quince said it may sell up to $75 million of its common shares from time to time to or through certain agents.

The company's shares were up 7.6% in after-hours activity.